Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy

2021 ◽  
Vol 23 (12) ◽  
Author(s):  
Alexandra Lainé ◽  
Travis T. Sims ◽  
Olivia Le Saux ◽  
Isabelle Ray-Coquard ◽  
Robert L. Coleman
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
The United States ◽  
Parp Inhibitors ◽  
Initial Therapy ◽  
Platinum Sensitive

scholarly journals Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer

2018 ◽  
Vol 36 (13) ◽  
pp. 1300-1307 ◽  
Author(s):  
Nicoletta Colombo ◽  
Gloria Huang ◽  
Giovanni Scambia ◽  
Eva Chalas ◽  
Sandro Pignata ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Brca Mutation ◽  
The United States ◽  
Turnaround Time ◽  
Genetic Counselors ◽  
Stakeholder Satisfaction ◽  
Use Of Resources ◽  
Counseling Model ◽  
Testing And Counseling

Purpose There is a growing demand for BRCA1/ 2 mutation ( BRCAm) testing in patients with ovarian cancer; however, the limited number of genetic counselors presents a potential barrier. To facilitate more widespread BRCAm testing in ovarian cancer, pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors. Patients and Methods The prospective, observational Evaluating a Streamlined Onco-genetic BRCA Testing and Counseling Model Among Patients With Ovarian Cancer (ENGAGE) study evaluated a streamlined, oncologist-led BRCAm testing pathway. The analysis population comprised 700 patients with ovarian cancer at 26 sites in the United States, Italy, and Spain. The primary objectives were to assess turnaround time and, using questionnaires, to evaluate stakeholder satisfaction (patients, oncologists, and geneticists or genetic counselors) with the oncologist-led BRCAm testing pathway. Results The median overall turnaround time was 9.1 weeks (range, 0.9 to 37.1 weeks), with median turnaround times in the United States, Italy, and Spain of 4.1 weeks (range, 0.9 to 37.1 weeks), 20.4 weeks (range, 2.9 to 35.4 weeks), and 12.0 weeks (range, 2.0 to 36.7 weeks), respectively. Patient satisfaction with the oncologist-led BRCAm testing pathway was high, with > 99% of patients expressing satisfaction with pre- and post- BRCAm test counseling. Oncologist satisfaction with the BRCAm testing pathway was also high, with > 80% agreeing that the process for performing BRCAm testing worked well and that counseling patients on BRCAm testing was an efficient use of their time. Oncologists expressed higher levels of satisfaction with the BRCAm testing pathway than did geneticists or genetic counselors. Conclusion The results of the ENGAGE study demonstrate that an oncologist-led BRCAm testing process is feasible in ovarian cancer. Development of local BRCAm testing guidelines similar to the one used in this study could allow faster treatment decisions and better use of resources in the management of patients with ovarian cancer.

BRCA1/2 Genetic Testing in the Community Setting

2002 ◽  
Vol 20 (22) ◽  
pp. 4485-4492 ◽  
Author(s):  
Wendy Y. Chen ◽  
Judy E. Garber ◽  
Suzanne Higham ◽  
Katherine A. Schneider ◽  
Katie B. Davis ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Genetic Testing ◽  
Cancer Prevention ◽  
Community Setting ◽  
The United States ◽  
Care Providers ◽  
Prevention Strategies ◽  
History Of ◽  
Genetic Results

PURPOSE: BRCA1/2 genetic testing has been commercially available in the United States since 1996. Most published reports described BRCA1/2 testing as research studies at large academic centers, but less is known about testing in the community. This study evaluates the process and early outcomes of BRCA1/2 genetic testing as a clinical service in the community setting. METHODS: Surveys were mailed to women in the United States whose health care providers ordered BRCA1/2 genetic testing from Myriad Genetic Laboratories from August 1998 through July 2000. Women tested at 149 large academic centers were excluded. Main outcome measures were demographic characteristics, recall of and satisfaction with the genetic testing process, and likelihood of pursuing cancer prevention strategies. RESULTS: Among the 646 respondents, 414 (64%) had a personal history of cancer and 505 (78%) had at least one first-degree relative with breast and/or ovarian cancer. Most subjects (82%) recalled discussions of informed consent before testing (median time, 30 minutes). Genetic results were conveyed during an office visit (57%), by telephone (39%), or by mail (3%). More than 75% of respondents were “very satisfied with the counseling received.” Cancer-free subjects with a germline mutation were more likely to consider prevention strategies after receiving the genetic results. CONCLUSION: Virtually all respondents had a personal and/or family history of breast/ovarian cancer. Although pretest and posttest communications were not standardized, overall satisfaction with clinical breast cancer genetic testing was high. Additional follow-up will provide data on future cancer prevention practices and cancer incidence.

The characterization of morbidly obese ovarian cancer patients in the United States: A study of demographic and socioeconomic status

2014 ◽  
Vol 133 ◽  
pp. 168
Author(s):  
J.K. Chan ◽  
K.W. Blansit ◽  
T.N. Tsuei ◽  
R.A. Brooks ◽  
S.M. Ueda ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Socioeconomic Status ◽  
Cancer Patients ◽  
The United States ◽  
Morbidly Obese

European/U.S. Comparison and Contrasts in Ovarian Cancer Screening and Prevention in a High-Risk Population

2017 ◽  
pp. 124-127
Author(s):  
Marian J. Mourits ◽  
G. H. de Bock
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
The United States ◽  
High Risk Population ◽  
Genome Wide Association Studies ◽  
Hereditary Ovarian Cancer ◽  
Ovarian Cancer Screening ◽  
Screening And Prevention

The history of screening and prevention of ovarian cancer among high-risk women in the United States and Europe is one of mutual inspiration, with researchers learning from each others’ findings and insights and collaborating with investigators from both sides of the Atlantic ocean. Examples of simultaneous and joint development of knowledge and scientific points of view include the paradigm shift from ovarian to fallopian tube high-grade serous cancer and the cessation of simultaneous adoption of ovarian cancer screening by clinicians in both the United States and Europe. Examples of joint efforts with fruitful results include international collaboration in large population-based, genome-wide association studies and in epidemiologic database studies. Research in the field of hereditary ovarian cancer is a great example of mutual inspiration and joint efforts for the purpose of improving knowledge and health care for women with hereditary ovarian cancer.

Trends in the Use of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer in the United States

2017 ◽  
Vol 72 (2) ◽  
pp. 93-94
Author(s):  
Alexander Melamed ◽  
Emily M. Hinchcliff ◽  
Joel T. Clemmer ◽  
Amy J. Bregar ◽  
Shitanshu Uppal ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
The United States

Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States

2016 ◽  
Vol 143 (2) ◽  
pp. 236-240 ◽  
Author(s):  
Alexander Melamed ◽  
Emily M. Hinchcliff ◽  
Joel T. Clemmer ◽  
Amy J. Bregar ◽  
Shitanshu Uppal ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
The United States

Abstract A02: Pediatric ovarian cancer in the United States: Incidence trends over four decades

2020 ◽  
Author(s):  
Kara M. Christopher ◽  
Eric Adjei Boakye ◽  
Justin M. Barnes ◽  
Matthew C. Simpson ◽  
Brittany J. Kline ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
The United States ◽  
Incidence Trends
Sign in / Sign up

Export Citation Format

Share Document